The makes of Xarelto (Bayer and Johnson & Johnson) took a major hit this week in terms of the future of there flagship drug. Xarelto is a member of a relatively new class of drugs called New Oral Anticoagulants (NOACs). NOACs are used for patients who suffer from a series of medical conditions including deep vein thrombosis (DVT) and atrial fibrillation (Afib). Afib is a serious medical condition that causes an irregular heartbeat when the patient does not have a heart valve defect.
In addition to Xarelto, Pradaxa, Eliquis and Savaysa are members of this new class of NOACs. Traditionally, before these medications were on the market, patients would take Warfarin (Coumadin) as a blood thinner. Warfarin is known to work and is relatively safe as long as patients do what they are told to do by their doctors. However, since patients do not always do what they are told, the drug is not always so convenient to take and may result in a serious internal bleeding disorder. However, if a patient does suffer from internal bleeding, a doctor can prescribe a reversal agent (antidote) to allow the patient to clot normally so the bleeding will stop. Continue reading